Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3 (Q35269318)

7 August 2017

title

Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3 (English)

1 reference

7 August 2017

1 reference

Liqun Chen

1

1 reference

7 August 2017

Benjamin A Mooso

2

1 reference

7 August 2017

Maitreyee K Jathal

3

1 reference

7 August 2017

Anisha Madhav

4

1 reference

7 August 2017

Sherra D Johnson

5

1 reference

7 August 2017

Elyse van Spyk

6

1 reference

7 August 2017

Margarita Mikhailova

7

1 reference

7 August 2017

Alexandra Zierenberg-Ripoll

8

1 reference

7 August 2017

Lingru Xue

9

1 reference

7 August 2017

Ruth L Vinall

10

1 reference

7 August 2017

Ralph W deVere White

11

1 reference

7 August 2017

Paramita M Ghosh

12

1 reference

7 August 2017

language of work or name

English

0 references

publication date

15 August 2011

1 reference

7 August 2017

published in

Clinical Cancer Research

1 reference

7 August 2017

volume

17

1 reference

7 August 2017

issue

19

1 reference

7 August 2017

page(s)

6218-6228

1 reference

Abiraterone and increased survival in metastatic prostate cancer

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Androgen receptor and growth factor signaling cross-talk in prostate cancer cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

The oncogenic potential of a prostate cancer-derived androgen receptor mutant

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Untangling the ErbB signalling network

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

The ErbB signaling network: receptor heterodimerization in development and cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Management of cancer of the prostate

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186857

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

26 September 2018

1 reference

12 December 2020

ErbB kinases and NDF signaling in human prostate cancer cells

1 reference

12 December 2020

HER-2 profiling and targeting in prostate carcinoma

1 reference

12 December 2020

Pathologic changes associated with androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

10.1158/1078-0432.CCR-11-1548

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference